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Ketamine was originally synthesised for use as a dissociative anaesthetic, and it remains widely used
legitimately for this indication. However, there is increasing evidence of non-medical recreational use of
ketamine, particularly in individuals who frequent the night-time economy. The population-level and sub-
population (clubbers) prevalence of recreational use of ketamine is not known but is likely to be similar, or
slightly lower than, that of other recreational drugs such as cocaine, MDMA, and amphetamine.
The predominant features of acute toxicity associated with the recreational use of ketamine are neuro-
behavioural abnormalities such as agitation, hallucinations, anxiety, and psychosis. Secondary to these,
individuals put themselves at greater riskof physical harm/trauma. Cardiovascular features (hypertension and
tachycardia) occur less frequently and the risk of death from recreational use is low and is predominately due
to the physical harm/trauma.
Long-term recreational use of ketamine can be associated with the development of psychological
dependence and tolerance. There are reports of gastro-intestinal toxicity, particularly abdominal pain and
abnormal liver function tests, and of neuropsychiatric disorders, typically a schizophrenia-like syndrome, in
long-term users. Finally, there are increasing reports of urological disorders, particularly haemorrhagic
cystitis, associated with long-term use. The management of these problems associated with the long-term use
of ketamine is largely supportive and abstinence from ongoing exposure to ketamine.
In this review we will collate the available information on the epidemiology of recreational use of ketamine
and describe the patterns of acute and chronic toxicity associated with its recreational use and the
management of this toxicity.
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K
etamine,2-(2-chlorophenyl)-2-(methylamino)-cy-
clohexanone is a dissociative anaesthetic that
was first synthesised in the United States in 1962
(1). It is listed by the World Health Organisation as an
essential medicine (2) and is widely used as a general
anaesthetic, both in veterinary and human practice. It is
characterised by its ability to cause unconsciousness,
amnesia, and analgesia whilst sparing airway reflexes and
maintaining haemodynamic stability (3). Ketamine is also
gaining favour as an alternative analgesia, particularly in
chronic non-cancer pain (4).
Its clinical use has always been limited by a hallucino-
genic effect, the so-called emergence delirium described
during its first human volunteer trial (1). This effect has
however led to recreational, non-medical misuse and
there has been evidence of this since 1967 (5). Common
street names for ketamine include ‘K’, ‘Special K’,
‘Kit-Kat’, and ‘Cat Valium’. It should be noted that
colloquial names of recreational drugs change with time
and differ between countries and communities, so it is not
possible to give a contemporaneous and complete list of
common street names for ketamine.
Ketamine is subject to control under recreational drug
legislation in many countries; it was added to Schedule
III in the United States in 1999 and in the United
Kingdom it was controlled as a Class C agent under the
Misuse of Drugs Act, 1971 in 2006. The prevalence and
geographic spread of ketamine misuse has increased
greatly over the past 20 years, and a pattern of adverse
effects that differs from that expected from occasional
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In addition, there is an accumulating literature on ketamine-
related chronic toxicity, in particular neuropsychological
and urological effects. This review will collate the
available information on the epidemiology of recreational
use of ketamine and describe the patterns of acute and
chronic toxicity associated with its recreational use.
Pharmacology
Ketamine produces dissociative anaesthesia by causing
electrophysiological dissociation between the limbic and
thalamoneocortical systems, resulting in a trance-like
cataleptic state characterised by unconsciousness, amne-
sia, deep analgesia but with intact ocular, laryngeal, and
pharyngeal reflexes (1). There are also sympathomimetic,
anti-cholinergic and analgesic effects: these start at sub-
anaesthetic doses, but persist throughout the period of
unconsciousness (1). Of note, ketamine is a chiral
molecule with two stereoisomers, and the S( )-isomer
is more potent for inducing general anaesthesia by a ratio
of 4:1 (6).
Ketamine is both water- and lipid-soluble, which
allows administration by many routes. Intravenous,
intramuscular, subcutaneous, oral, nasal, and rectal
administration are described both therapeutically (3)
and for recreational, non-medical ketamine misuse (7).
Extensive first-pass hepatic metabolism of ketamine to its
main metabolite norketamine substantially reduces its
bioavailability following either oral or rectal administra-
tion (see Table 1) (3, 8 10). Ketamine has a short a half-
life (2 4 min) and longer b half-life (8 16 min), and its
effects vary according to plasma concentration. Analge-
sia begins at 100 ng/ml, drowsiness and perceptual
distortions occur between 50 200 ng/ml, and general
anaesthesia requires 2,000 3,000 ng/ml, with awakening
occurring when levels fall to 500 1,000 ng/ml (3).
Ketamine has two major metabolites: norketamine,
which has one-third the potency of ketamine (11) and
dehydronorketamine. Norketamine is produced by cyto-
chrome P450-mediated N-demethylation, mainly by
CYP3A4 but with minor contributions from CYP2C9
and CYP2B6 (12). Norketamine is then dehydrogenated
to dehydronorketamine and both these metabolites
undergo hepatic conjugation. Ketamine and its metabo-
lites are all renally excreted, mostly as conjugates (80%)
and dehydronorketamine (16.2%), with very small pro-
portions as ketamine (2.3%) or norketamine (1.6%) (13).
They can be detected in the urine for many days:
ketamine, 5 11 days; norketamine, 6 14 days; dehydro-
norketamine, 10 days (14, 15).
Ketamine has activity at several receptors. Primarily, it
is an antagonist of the glutaminergic N-methyl-D-
aspartate receptor (NMDA-R), both centrally and in the
spinal cord (16). Ketamine binds non-competitively to
the so-called phencyclidine-binding site of the NMDA-R
and prevents neuronal Ca
2  influx, with the S( )-isomer
showing 3 4 times greater affinity (17). This disrupts
cortical-cortical and cortical-subcortical signalling (18),
producing dissociative anaesthesia, interference with
neuronal plasticity, learning and memory, analgesia at
central and spinal cord level, as well as interruption of the
central sensitization core to chronic pain syndromes (3).
Norketamine is also an NMDA-R antagonist, contribut-
ing to the effects of ketamine (19).
Ketamine is also reported to be a weak agonist of m-
opioid receptors (20), though the NMDA-R antagonism
is believed to be more important for its analgesic activity.
Its sympathomimetic activity is reportedly due to agonist
activity at a1- and b2-adrenoceptors (21), as well as
catecholamine re-uptake blockade (22). Ketamine also
has a profound anticholinergic effect, produced by
antagonism of the central nervous system muscarinic
acetylcholine receptors (23) and inhibition of acetylcho-
linesterase (24), although one of the resultant effects*
bronchodilatation*may also be caused by a direct
antagonism of endothelin-1-induced bronchial smooth
muscle constriction (25). In a rat model, acute ketamine
administration resulted in increased dopamine and 5-
hydroxyindoleacetic levels in the medial prefrontal cortex
(26); however, repeated daily ketamine administration for
7 days attenuated dopamine but enhanced 5-hydroxyin-
doleacetic acid release. Finally, ketamine potentiates
Table 1. Ketamine pharmacokinetics, based on route of administration
Intravenous Intramuscular Oral Rectal Nasal
Induction of general anaesthesia (3) 1 2 mg/kg* 2 4 mg/kg 8 10 mg/kg 5 mg/kg
0.5 1 mg/kg**
Typical recreational dose (single
dose, mg) (8)***
50 100 75 125 200 300 No data 60 250
Onset of effect (3) Seconds 1 5 min 15 20 min No data 5 10 min
Duration of effect (3) 30 45 min 30 45 min 60 120 min No data 45 60 min
Bioavailability (%) 100% 93% (9) 17% (9) 25% (10) 25 50% (10)
*Racemic ketamine, **S( )-ketamine, ***Typical recreational dose is 10 25% of the effective general anaesthetic dose (7).
Sarbjeet S. Kalsi et al.
2
(page number not for citation purpose)
Citation: Emerging Health Threats Journal 2011, 4: 7107 - DOI: 10.3402/ehtj.v4i0.7107gamma-aminobutyric acid (GABA) synaptic inhibition,
through weak GABAA receptor agonism (27, 28), but this
is not thought to be clinically significant (3).
Recreational, non-medical ketamine is available to
users in powdered, capsule, and liquid formulations.
Most recreational use is by nasal insuffulation, with
ketamine powder insuffulated either directly or off the
surface of objects such as keys or ketamine spoons or
vaporised in solution (8). In tablet form, it is often
admixed with other pharmacologically active substances
such as amphetamine, caffeine, cocaine, amphetamine,
and heroin (8). Importantly, recreational ketamine use
often occurs with co-use of other substances, and
potentially serious adverse pharmacological and toxico-
logical interactions can occur with concomitant use of
either central nervous system depressants (e.g. ethanol,
opioids, barbiturates, benzodiazepines) or sympathomi-
metics (e.g. cocaine and amphetamines) (8).
Epidemiology of recreational use of ketamine
Recreational use of ketamine was first reported amongst
those with access to the drug, particularly medical
professionals, in 1967 (5). It then spread beyond this
group to the community-at-large, firstly in the United
States and then internationally, in association with the
‘rave’ dance sub-culture of the 1980 1990s (7, 29). More
recently it has become part of the current ‘post-rave’
clubbing and youth dance culture, as a mainstream ‘club
drug’ alongside drugs such as 3,4-methylenedioxy-
methampthetamine (MDMA or ‘ecstasy’), cocaine, and
gamma-hydroxybutyrate (GHB) (30).
The precise prevalence of recreational, non-medical
ketamine use is unknown; small single country studies
suggest that the background population use rates of
ketamine are low, between 0.1 and 4% of those surveyed
(summarised in Table 2) (31 34). In addition, data on the
population prevalence rates of ketamine is not routinely
collected in most countries and is not included in reports
from organisations such as the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) and
the United Nations Office on Drugs and Crime
(UNODC). Lifetime and ‘recent’ recreational use of
ketamine is significantly higher in those frequenting the
night-time economy (e.g. discotheques, nightclubs, dance/
music events; Table 3) (35 38). Four main groups of users
are commonly described: regular drug users in the dance
music setting, members of the men-who-have-sex-with-
men (‘gay’) club/party scene, injecting heroin users, and
self-exploratory people (39). Recreational ketamine use is
commonly part of poly-substance use and is taken
together with another club drug, ethanol, or stimulant
(35, 40).
Geographically, recreational use of ketamine use is
seen across the world, but it appears to be most common
in East and South-East Asia, potentially because of its
relatively low price compared to other psychomimetic
drugs, particularly MDMA (41). Global reports of
ketamine seizure rose from negligible amounts in 1999
to over 11 metric tonnes in 2007, with nearly all of this
in East and South-East Asia, where ketamine seizures
exceeded that of heroin (41, 42). Hong Kong reported
ketamine as the second-most popular drug of abuse after
heroin for the period 2007 2010 (43). Importantly, in the
last reported year, 2008, for the first time a substantial
minority of seizures (14%) were reported from outside
of this region, suggesting a widening of ketamine supply
(41).
It is often stated that the bulk of illicitly available
ketamine is derived by diversion of legitimate veterinary
and medical supplies; however, illicit manufacturing
laboratories have now also been reported, particularly
in China and South-East Asia (41).
Ketamine-related acute toxicity
The main acute toxicity associated with recreational use
of ketamine is related to its psychedelic/hallucinogenic
properties. Systemic toxicity with cardiovascular effects
can occur, but generally clinical features are related to
physical harm, either because of ketamine-induced ag-
gression and agitation or because an individual believes
that they can do things without suffering significant
injury (e.g. jumping off a building) due to its dissociative
features. Any description of acute ketamine toxicity is
complicated by the fact ketamine is commonly part of a
poly-substance use scenario. In 116 individuals with acute
recreational drug toxicity presenting to an Emergency
Table 2. Ketamine use from population surveys, reported by individual country where data has been obtainable
Country, Year Reference % Lifetime ketamine
use
% Ketamine use
in past year
Age range (years)
Australia, 2007 (31) 1.1 0.2 14 to  40
Canada, 2009 (32) 2.2 1.6 12 18
United Kingdom, 2009 2010 (33) 4.0 1.7 16 24
2.0 0.5 16 59
United States, 2006 (34) 0.1 B0.01  12
Recreational ketamine toxicity
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mine use, 89% had used at least one other recreational
drug or ethanol (suggesting ketamine is often part of a
polydrug repertoire) (44). It is therefore important in
patients presenting with acute toxicity after ketamine use,
particularly if systemic features are present, to consider
that this toxicity may, in part, be due to the co-ingested
drug(s).
Neuro-behavioural effects
Recreational use of ketamine can cause a number of
troublesome neuro-behavioural/neuropsychiatric effects.
Users may be become agitated, aggressive, paranoid, and
display dissociative-type symptoms. The content of
hallucinations may be unwanted, which are typically
referred to by users as ‘falling into the K-hole’, and in
some cases can be significantly unpleasant. In healthy
volunteers, an acute sub-anaesthetic dose of 0.1 0.5 mg/
kg ketamine is sufficient to induce schizotypal and
dissociative symptoms such as altered perception, as
well as impaired performance of tests of vigilance, verbal
fluency, word recall (45).
Risk of physical harm
One of the biggest concerns surrounding acute ketamine
use is that it reduces awareness of the immediate
environment, thus exposing the user to potential physical
harm (46). The reduced awareness encompasses a sense
of depersonalisation, derealisation, reduced perception of
pain, and potentially unconsciousness. This is com-
pounded by users frequently experiencing lack of co-
ordination, temporary paralysis, inability to move,
blurred vision, and inability to speak (39). As such, users
put themselves at risk of significant injury, through
jumping from heights, road traffic accidents, drowning,
and hypothermia (secondary to incomplete drowning or
prolonged environmental exposure (7).
Despite media and public concern about the potential
for ketamine to be involved in drug-facilitated sexual
assault, it is unusual for ketamine to be detected in this
scenario. On screening, only 3 of 1,014 cases in the
United Kingdom (47) and 2 of 184 cases from Canada
(48) tested positive for ketamine. Drug-driving, on the
other hand is more common, and ketamine was asso-
ciated with 9% of fatal drug-and-alcohol-related single-
motor-vehicle collisions in Hong Kong during 1996 2000
(49). During 2007, a single trauma centre in Hong Kong
reported 4.5% of drivers involved in non-fatal crashes
tested positive for ketamine (50).
Cardiovascular toxicity
During ketamine anaesthetic induction, tachycardia and
hypertension precede unconsciousness (1) and this effect
is also commonly seen with the sub-anaesthetic doses
used for recreational ketamine use. The most common
reported cardiovascular effect in patients with acute
ketamine toxicity is a self-resolving sinus tachycardia
with chest pain and palpitations less commonly reported
(44, 51). There have also been isolated reports of acute
pulmonary oedema following parental ketamine use,
although it is difficult to be certain from these reports
whether the pulmonary oedema was due to ketamine or
some other factor (52 54). Interestingly, in an in vitro
model, alveolar S( )-ketamine reduced alveolar fluid
clearance, although the doses required were not clinically
relevant (55).
Risk of death from overdose
Ketamine has a wide therapeutic range and the median
lethal dose (LD50) in animals is 100 times the average
therapeutic intravenous dose (3), which makes death from
overdose difficult. Indeed, death and non-fatal emergen-
cies attributed to ketamine use are considered to be very
rare (37). When ketamine is reported in post-mortem
samples, it is often either alongside another intoxicant or
in the setting of trauma. From the forensic literature
regarding death following recreational ketamine use,
blood ketamine concentrations within the range of 0.1
to 7.0 mg/l have been reported alongside the presence of
another co-ingestant such as ethanol, opiates, ampheta-
mine, or cocaine (56 59). Of the 23 deaths in which
ketamine was identified in post-mortem samples in the
United Kingdom between 1993 and 2006, only 4 were
attributed to lone ketamine poisoning (60). Similarly, in
Table 3. Ketamine use in the club and dance music setting, reported by country
Country Reference % Lifetime ketamine use % Recent ketamine use Comments
Canada (35) 8.6 Recently at last rave
Czech Republic (36) 6.7 0.3 Recently at last month
France (36) 16.4
Italy (36) 10.8
Hungary (36) 20.9
United Kingdom (37) 67.8 32.4 Recently in previous month
Taiwan (38) 47.0 Based on urine screening of
dance club attendees
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ketamine was identified in post-mortem samples of
persons identified as recreational drug users, 12 were
poly-substance overdoses and 2 died as a result of trauma
(58).
Management of acute ketamine toxicity
The management of acute ketamine toxicity is largely
supportive and involves removing an individual from
excessive auditory and visual stimulation until symptoms
resolve. In cases of severe symptoms, particularly agita-
tion/aggression, benzodiazepines may be required (51).
Most patients typically improve rapidly following acute
ketamine toxicity and in those with significant systemic
symptoms and/or prolonged ongoing symptoms, clini-
cians should consider whether there is an alternative
diagnosis contributing to the individual’s clinical condi-
tion (51).
Chronic toxicity related to recreational ketamine
use
Recently, the long-term effects of recreational, non-
medical ketamine use have come under scrutiny. We will
summarise here the data on associated neuropsychologi-
cal effects, neurotoxicity, dependence, and urological and
gastrointestinal pathology.
Neuropsychological effects and neurotoxicity
Ketamine is associated with both neuropsychiatric
symptoms and direct neurotoxicity. As described above,
ketamine can cause several acute neuropsychiatric effects.
Acute and acute-on-chronic use of ketamine has been
shown to be associated with impaired information hand-
ling within working memory and episodic memory, aswell
as semantic processing deficits (61, 62). Men appear to be
moreaffectedbytheseeffectsthanwomen(63).Forupto3
days following ketamine use, subjects are threefold likelier
to report unpleasant dreams (64).
Long-term ketamine users appear to have more
pronounced and persistent neuropsychiatric symptoms,
generally characterised as schizophrenia-like symptoms.
In a recent case-control study comparing frequent
ketamine users, defined as use at least four-times-a-
week, with infrequent users, abstinent users, poly-drug
users, and non-drug users, frequent ketamine use was
associated with impairment of working memory, episodic
memory, executive function and psychological well-being
(65). These frequent users were reported as taking an
average of 2.77 g of ketamine an average of 20 days per
month. The same group were then followed up for a year,
and the frequent ketamine users with increasing ketamine
doses were more likely to have cognitive deficits, espe-
cially with spatial working memory and pattern recogni-
tion memory tasks, and both short- and long-term
memory was affected (66). From the same studies,
delusional thinking was shown to be correlated positively
with the amount of ketamine used by frequent users
and persisted despite abstinence (65). A dose-dependent
relationship was reported on 1-year follow-up, with
frequent users being more delusional than infrequent,
abstinent, and non-users, respectively (66). Superstitious
conditioning, a form of associative learning, is also more
common amongst frequent ketamine users and this
process may precede outright delusional thinking (67).
Frequent ketamine use is also typified by increased
dissociative and depressive symptoms (66), as well as a
subtle visual anomaly (68). It is not certain how ketamine
causes these effects, but antagonism of the NMDA-R is
thought to be important, as is dopaminergic depletion in
the prefrontal cortex (3, 26, 69).
Ketamine is also directly neurotoxic. Animal studies
have shown that apoptotic neuro-degeneration is induced
by NMDA-R antagonists, including ketamine, in the
developing rodent brain (70). This effect for ketamine has
since been shown to be more marked in older rats and is
synergistic with nitrous oxide (71 73); it was ameliorated
by GABAA agonism with benzodiazepines, and pre-
vented by neuronal nitrous oxide synthase antagonism
with 7-nitroindazole (73, 74). This last finding implicates
endogenous nitrous oxide in ketamine-related neurotoxi-
city. In monkeys, neuronal death was observed after
ketamine anaesthesia administered for 9 hours or more
but not for 3 hours duration (75). Recently, evidence for
harm in humans following frequent ketamine use has
been presented, with bilateral frontal and left tempor-
oparietal white matter degeneration shown on brain
magnetic resonance imaging being positively correlated
to self-reported ketamine dosages (76).
Tolerance and dependency
There is evidence that ketamine causes a psychological,
rather than a physical, dependency. The World Health
Organisation’s International Classification of Diseases
(ICD-10) defines substance dependence as ‘a cluster of
behavioural, cognitive, and physiological phenomena that
develop after repeated substance use and that typically
include a strong desire to take the drug, difficulties in
controlling its use, persisting in its use despite harmful
consequences, a higher priority given to drug use than to
other activities and obligations, increased tolerance, and
sometimes a physical withdrawal state’ (77). This defini-
tion holds true for frequent, long-term ketamine use. In
particular, ketamine use can be uncontrolled, over-
prioritised, and linked with tolerance but does not cause
a physical withdrawal state.
Anecdotally, ketamine use in humans is characterised
by binging, the drug being repeatedly used until a user’s
supply has been exhausted (78, 79). This phenomenon is
also seen in pigeons and monkeys, who repeatedly self-
administer freely available ketamine, suggesting that it is
Recreational ketamine toxicity
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Tolerance is considered to be a major factor in the
development of dependency (82) and is a well-recognised
characteristic of frequent ketamine use, with intranasal
doses of up to 130 mg/kg reported (79, 81). Tolerance is
likely explained by ketamine auto-induction of metabo-
lism. Ketamine pretreatment doubles its hepatic micro-
somal metabolism in rats, and both the catalytic activity
and protein expression of the rat microsomal cytochrome
P-450 system is enhanced by repeated daily ketamine
administration (83, 84). Unsurprisingly, frequent keta-
mine use is associatedwith increasing doses to achieve the
same effect, with a sixfold increase in dosage reported
during initiation of chronic use, and frequent users using
twice the dose of infrequent users (66, 85).
Urological toxicity
Recently lower urinary tract symptoms (LUTS) of
dysuria, increased frequency of small volume micturition,
suprapubic pain and, if severe, painful haematuria have
been reported amongst long-term ketamine users. There
have been no large epidemiological studies, but pilot
studies suggest that up to a third of long-term ketamine
users may be affected: pooling together the results of
three small surveys of frequent users, 50 of 157 ketamine
users admitted to LUTS (84 87). In 2007, investigators
from Canada linked these symptoms with ulcerative
cystitis (88); additionally, those severely affected may
also experience obstructive nephropathy (89).
There is evidence from beyond the recreational use
setting linking ketamine with urological pathology. In an
animal study performed following the reports of human
pathology, mice administered intraperitoneal ketamine
for up to 6 months demonstrated pathological changes,
with mononuclear infiltration occurring throughout the
urological tract in the glomeruli, ureters, and bladders
(90). Four cases have also been reported from the
palliative care setting linking analgesic ketamine use
with LUTS (91, 92).
To date, there have been three retrospective case series
(n]10) published, covering 93 patients reporting chronic
urological effects in long-term recreational ketamine
users (see Table 4) (86, 93, 94). In all of these, patients
self-reported ketamine use in excess of 3 months with
ketamine use preceding LUTS. Except for one case, all
had either sterile or contaminant-only urinary cultures.
Reduced bladder volume was reported in three-quarters
(57/77) and hydronephrosis in more than half (38/70) of
those who had an appropriate investigation undertaken.
Commonly, reduced bladder volume was associated with
bladder wall thickening, detrusor instability, and vesi-
coureteric reflux, which explains the hydronephrosis as
potentially a secondary effect of the bladder pathology
(86, 93). Alternatively, hydronephrosis could also be a
result of either peri-ureteric thickening or intraureteric T a b l e
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(86, 89, 93). All of those who had cystoscopy had
demonstratable cystitis, with abnormal histology being
reported in 32 of 34 biopsies. Unusual features were peri-
ureteric thickening (3/71) and raised serum creatinine (8/
92), with some patients showing ultrasonographic evi-
dence of papillary necrosis (86); it is unknown if this
represents a primary renal insult or arises as a conse-
quence of the hydronephrosis.
Histologically, bladder biopsies from patients with
ketamine-associated cystitis show a consistent picture of
urothelial ulceration, with eosinophilic infiltration of the
laminapropriawith surrounding reactive urothelial atypia
(88, 94, 95). The appearances are similar to carcinoma
in situ, with nuclear enlargement and disorganisation,
high p53 immunoreactivity, and moderate-to-high Ki67
immunoreactivity; importantly, what distinguishes the
ketamine-related changes from carcinoma in situ is
that the ketamine-related biopsies are negative for CK20
(95).
The cause of the bladder pathology is unknown. Given
that there are reports of adulterants added to ‘street’/
illegal ketamine, it is possible that the urinary tract
problems are related to the adulterants rather than to
ketamine itself. However, in the animal study discussed
above, mice were only exposed to intraperitoneal keta-
mine and still developed mononuclear infiltration occur-
ring throughout the urological tract, in the glomeruli,
ureters, and bladders (90). In addition, there are four
reported cases from the palliative care setting in patients
using pharmaceutical-grade analgesic ketamine who
developed LUTS (91, 92). It is likely on the basis of
this evidence, that the urinary tract pathology seen is
related directly to ketamine and/or its metabolites.
Additionally, the bladder is exposed to ketamine and its
active metabolites for over a week following a single dose
of ketamine (14, 15), which suggests frequent ketamine
users would have a prolonged exposure. The evidence for
a dose-dependent relationship is strengthened by evi-
dence from a case report of a palliative care patient whose
urinary symptoms paralleled the use, discontinuation,
reintroduction, and repeat discontinuation of analgesic
ketamine (91).
Abstinence of continuing ketamine use is central to
managing patients with urological pathology (86, 94, 96).
There are no reports of spontaneous resolution of either
symptoms or pathology in persistent ketamine users, and
both recurrent symptoms and/or worsening pathology
are reported in those who return to ketamine use (89, 91).
A number of therapies have been explored for the
management of ketamine associated urological problems.
Some authors have described symptom relief with the use
of elmiron (pentosan polysulphate sodium), which is a
low molecular weight heparin-like compound that is
thought to help increase the glycosaminoglycan layer of
the damaged bladder wall urothelium (88). Intravesical
hyaluronic acid has also been used (94, 97 99). Hyaluro-
nic acid is a mucopolysaccharide and it is thought that it
acts as a urothelial protective barrier. Its use has been
described in both general and ketamine-related intersti-
tial and haemorrhagic cystitis (94, 97 99). In one series of
six patients with ketamine-related bladder pathology and
LUTS, weekly intravesical hyaluronic acid for 1 month
resulted in improvement in painful bladder, frequency,
and haematuria (94). Surgical intervention, such as
augmentation enterocystoplasty or cystectomy with con-
duit diversion, is generally considered a last resort in
patients who have continued symptoms and haematuria
despite the above therapies and abstinence from ketamine
(93, 94, 100).
Gastrointestinal toxicity
Regular ketamine use is associated with vague abdominal
pains of unknown aetiology, colloquially termed ‘K-
Cramps’ (7). Recently, certain authors have described
gastric and hepatic pathology in long-term ketamine
users investigated for abdominal pains.
In a small retrospective analysis of 37 recreational
ketamine users from Hong Kong, typical symptoms of
epigastric pain, with or without vomiting, was associated
with biopsy-proven Helicobacter Pylori-negative gastritis
(101). These symptoms were improved by self-reported
abstinence, but neither the abstinence nor gastritis
resolution was objectively confirmed. In that same
analysis, abnormal liver function tests were reported,
but no statistical relationship to symptoms was detected
(101). Abnormal liver function tests, irrespective of
associated pain, have also been reported elsewhere after
clinical ketamine use and non-medical ketamine use (89,
101 105). S( )-ketamine has recently been shown to be
directly hepatotoxic in human hepatoma G2 cells in vitro
and this occurs at concentrations compatible with
ketamine use (105). However, this effect has not been
shown to cause abdominal pains.
Choledochal cysts, benign cystic dilatations of the
common bile duct, in association with abnormal liver
function tests have been described in ketamine users from
the United Kingdom and Hong Kong (89, 103, 104). One
chronic ketamine user from the United Kingdom had a
dilated common bile duct that regressed with abstinence
but recurred following a return to ketamine use (89). All
five patients reported from Hong Kong were diagnosed
with choledochal cysts following investigations for re-
current epigastric pain and abnormal liver function tests
and improvement in both symptoms and common bile
duct dilatation occurred with self-reported abstinence. It
is unclear what the mechanism for these effects is.
Recreational ketamine toxicity
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Recreational, non-medical ketamine use is an important
public health issue, with evidence of its increasing use in
certain population sub-groups, the youth clubbing scene
in particular. In the acute setting, the neuro-behavioural
and neuropsychiatric effects of ketamine increase the risk
of injury and harm to the individual. In the long-term
there is evidence of psychological dependency and strong
evidence for deleterious neuropsychiatric and urological
effects. Long-term users may develop schizophrenia-type
symptoms, have poor psychological well-being, memory
difficulties, and are at risk of haemorrhagic cystitis with
significant associated lower urinary tract symptoms.
More work is still needed to better elucidate the
epidemiology of ketamine use and the pathophysiological
basis of the chronic neuropsychiatric and urological
harms.
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